Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20120215009014N484
IRCT20120215009014N484
Not Yet Recruiting
Phase 3

Effect of Empagliflozin as adjunctive therapy versus placebo on serum level of oxidative stress biomarkers in diabetic patients with systolic heart failure: a double-blind randomized clinical trial

Hamedan University of Medical Sciences0 sites80 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Hamedan University of Medical Sciences
Enrollment
80
Status
Not Yet Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Age 18 to 80 years
  • •Type 2 diabetes
  • •Controlled systolic heart failure for at least 6 months
  • •Hemoglobin A1c less than 6\.5
  • •Stable clinical and hemodynamic status

Exclusion Criteria

  • •Pregnancy or breastfeeding
  • •Inflammatory, respiratory, infectious or malignant diseases
  • •History of myocardial infarction, stroke, angioplasty or CABG in the last 3 months
  • •Embedding pacemaker in the last 3 months
  • •Use of anti\-oxidant or anti\-inflammatory drugs or corticosteroids in the last 3 months

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not Yet Recruiting
Phase 3
Effect of Empagliflozin as adjunctive therapy on serum level of oxidative stress biomarkers
IRCT20120215009014N486Hamedan University of Medical Sciences80
Not Yet Recruiting
Phase 3
Comparison of therapeutic effect of Empagliflozin (Gloripa) and Sitagliptin (Ziptin) on type 2 Diabetic patients
IRCT20200810048355N1Vice Chancellor for Research, Islamic Aazad University, Najafabad branch128
Completed
N/A
Evaluation of the effect of empagliflozin in combination with pioglitazone on fatty liver diseaseFatty liver.Fatty (change of) liver, not elsewhere classifiedK76.0
IRCT20240208060939N1Artesh University of Medical Sciences80
Recruiting
Phase 3
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02
IRCT20220902055858N1Shahre-kord University of Medical Sciences90
Not Yet Recruiting
Phase 3
Assessment of effectiveness of Empagliflozin in the management of Anemia in diabetes patients
CTRI/2024/02/063292SRM Insitute of Science and Technology